These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29398430)
21. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764 [TBL] [Abstract][Full Text] [Related]
22. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386 [TBL] [Abstract][Full Text] [Related]
24. Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. Li S; Zhang Y; Zhu CG; Guo YL; Wu NQ; Gao Y; Qing P; Li XL; Sun J; Liu G; Dong Q; Xu RX; Cui CJ; Li JJ J Clin Lipidol; 2016; 10(6):1344-1352. PubMed ID: 27919351 [TBL] [Abstract][Full Text] [Related]
25. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
26. Preventing early cardiovascular death in patients with familial hypercholesterolemia. Repas TB; Tanner JR J Am Osteopath Assoc; 2014 Feb; 114(2):99-108. PubMed ID: 24481802 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159 [TBL] [Abstract][Full Text] [Related]
28. Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation. Petrov I; Postadzhiyan A; Vasilev D; Kasabov R; Tokmakova M; Nikolov F; Istatkov V; Zhao B; Mutafchiev D; Petkova R Adv Ther; 2021 May; 38(5):2323-2338. PubMed ID: 33754300 [TBL] [Abstract][Full Text] [Related]
29. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
30. Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Turgeon RD; Barry AR; Pearson GJ Can Fam Physician; 2016 Jan; 62(1):32-7. PubMed ID: 26796832 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
32. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM Med Hypotheses; 2018 Dec; 121():60-63. PubMed ID: 30396495 [TBL] [Abstract][Full Text] [Related]
33. Lipoprotein(a), cardiovascular disease, and contemporary management. Jacobson TA Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706 [TBL] [Abstract][Full Text] [Related]
34. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Paquette M; Brisson D; Dufour R; Khoury É; Gaudet D; Baass A J Clin Lipidol; 2017; 11(5):1161-1167.e3. PubMed ID: 28801029 [TBL] [Abstract][Full Text] [Related]
36. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Pérez de Isla L; Alonso R; Mata N; Fernández-Pérez C; Muñiz O; Díaz-Díaz JL; Saltijeral A; Fuentes-Jiménez F; de Andrés R; Zambón D; Piedecausa M; Cepeda JM; Mauri M; Galiana J; Brea Á; Sanchez Muñoz-Torrero JF; Padró T; Argueso R; Miramontes-González JP; Badimón L; Santos RD; Watts GF; Mata P Circulation; 2017 May; 135(22):2133-2144. PubMed ID: 28275165 [TBL] [Abstract][Full Text] [Related]
37. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
38. Familial hypercholesterolemia: Experience in the Lipid Clinic of Alava. Pérez García L Clin Investig Arterioscler; 2018; 30(5):224-229. PubMed ID: 29980385 [TBL] [Abstract][Full Text] [Related]
39. Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. Bogsrud MP; Langslet G; Wium C; Johansen D; Svilaas A; Holven KB J Clin Lipidol; 2018; 12(2):375-382. PubMed ID: 29310990 [TBL] [Abstract][Full Text] [Related]
40. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]